Reduction in HTLV‐I proviral load and spontaneous lymphoproliferation in HTLV‐I–associated myelopathy/tropical spastic paraparesis patients treated with humanized anti‐tac
Abstract
Human T‐lymphotropic virus type I (HTLV‐I)‐associated myelopathy/tropical spastic paraparesis (HAM/TSP) is a neurological disease that results from an interaction of retroviral infection and immune activation. In this study, five doses (1 mg/kg) of humanized anti‐Tac antibody were administered to 9 HAM/TSP patients at weeks 0,2,6,10, and 14. Preliminary immunological studies on HAM/TSP patients treated with humanized anti‐Tac indicate that there is a selective down‐regulation of activated T cells and a decrease in the HTLV‐I viral load in peripheral blood lymphocytes, most likely through the selective removal of HTLV‐I–infected, activated CD4+ lymphocytes.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Daclizumab was found to lower PVL in PBMCs with selective downregulation of HTLV-1-infected CD4+ T cells.
“The first molecular, targeted mAb specific for HAM was against the Humanized IL-2 receptor α-chain antibody (anti-Tac or daclizumab), which was found to lower PVL in PBMCs with selective downregulation of HTLV-1-infected CD4+ T cells [249].”
From Current State of Therapeutics for HTLV-1 (2024) · cites this paper as [249]
Significant improvements to patient outcome were not observed in the nine patients treated with daclizumab.
“However, significant improvements to patient outcome were not observed in the nine patients treated.”
From Current State of Therapeutics for HTLV-1 (2024) · cites this paper as [249]
Cites
Poiesz, B. J., Ruscetti, F. W., Gazdar, A. F., Bunn, P. A., Minna, J. D., & Gallo, R. C. (1980) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.77.12.7415 · Cited by 5,043 · see citing works
ANTIBODIES TO HUMAN T-LYMPHOTROPIC VIRUS TYPE-I IN PATIENTS WITH TROPICAL SPASTIC PARAPARESIS
Gessain, A., Vernant, J. C., Maurs, L., Barin, F., Gout, O., Calender, A., & de Thé, G. (1985) · The Lancet · doi:10.1016/s0140-6736(85)92734-5 · Cited by 2,812 · see citing works
HTLV-I ASSOCIATED MYELOPATHY, A NEW CLINICAL ENTITY
Osame, M., Usuku, K., Izumo, S., Ijichi, N., Amitani, H., Igata, A., Matsumoto, M., & Tara, M. (1986) · The Lancet · doi:10.1016/s0140-6736(86)91298-5 · Cited by 2,381 · see citing works
Interleukin-2–Receptor Blockade with Daclizumab to Prevent Acute Rejection in Renal Transplantation
Vincenti, F., Kirkman, R. L., Light, S. E., Bumgardner, G. L., Pescovitz, M. D., Halloran, P. F., Neylan, J. F., Wilkinson, A. H., Ekberg, H., Gaston, R. S., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801153380304 · Cited by 861 · see citing works
Self-citationJacobson, S., Shida, H., McFarlin, D. E., Fauci, A. S., & Koenig, S. (1990) · Nature · doi:10.1038/348245a0 · Cited by 614 · see citing works
Self-citationInoue, J., Seiki, M., Taniguchi, T., TSURU, S., & Yoshida, M. (1986) · The EMBO Journal · doi:10.1002/j.1460-2075.1986.tb04583.x · Cited by 506 · see citing works
Maruyama, M., Shibuyà, H., Harada, H., Hatakeyama, M., Seiki, M., Fujita, T., Inoue, J., Yoshida, M., & Taniguchi, T. (1987) · Cell · doi:10.1016/0092-8674(87)90437-5 · Cited by 425 · see citing works
Isolation of an HTLV-1-like retrovirus from patients with tropical spastic paraparesis
Jacobson, S., Raine, C. S., Mingioli, E. S., & McFarlin, D. E. (1988) · Nature · doi:10.1038/331540a0 · Cited by 246 · see citing works
Self-citationInoue, J., Yoshida, M., & Seiki, M. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.11.3653 · Cited by 243 · see citing works
Ta, W., White, J., Goldman, C. K., Top, L. E., Grant, A., Bamford, R. N., Roessler, E., Horak, I. D., Zaknoen, S. L., & Kasten-Sportès, C. (1993) · Blood · doi:10.1182/blood.v82.6.1701.1701 · Cited by 207 · see citing works
Self-citationItoyama, Y., Minato, S., Kira, J., Goto, I., Sato, H., OKOCHI, K., & Yamamoto, N. (1988) · Neurology · doi:10.1212/wnl.38.8.1302 · Cited by 204 · see citing works
Tendler, C. L., Greenberg, S. J., Blattner, W. A., Manns, A., Murphy, E. L., Fleisher, T. A., Hanchard, B., Morgan, O., Burton, J. D., & Nelson, D. L. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.13.5218 · Cited by 192 · see citing works
Self-citationLehky, T., Levin, M. C., Flerlage, N., Jacobson, S., Fox, C. H., Koenig, S., Izumo, S., Sato, E., Osame, M., & Raine, C. S. (1995) · Annals of Neurology · doi:10.1002/ana.410370206 · Cited by 174 · see citing works
Self-citationTa, W., Goldman, C. K., Bongiovanni, K. F., Sharrow, S. O., Davey, M., Cease, K., Greenberg, S., & Longo, D. (1988) · Blood · doi:10.1182/blood.v72.5.1805.1805 · Cited by 169 · see citing works
Junghans, R. P., Waldmann, T. A., Landolfi, N. F., Avdalovic, N. M., Schneider, W. P., & Queen, C. (1990) · PubMed · Cited by 150 · see citing works
Self-citationJacobson, S., Zaninovic, V., Mora, C. A., Rodgers‐Johnson, P., Sheremata, W. A., Gibbs, C. J., Gajdusek, D. C., & McFarlin, D. E. (1988) · Annals of Neurology · doi:10.1002/ana.410230744 · Cited by 126 · see citing works
Self-citationReduced immunogenicity and improved pharmacokinetics of humanized anti-Tac in cynomolgus monkeys
Hakimi, J., Chizzonite, R., Luke, D. R., Familletti, P. C., Bailon, P., Kondas, J. A., Pilson, R., Lin, P., Weber, D. V., & Spence, C. R. (1991) · The Journal of Immunology · doi:10.4049/jimmunol.147.4.1352 · Cited by 103 · see citing works
Kira, J.-I., Fujihara, K., Itoyama, Y., Goto, I., & Hasuo, K. (1991) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(91)90192-a · Cited by 96 · see citing works
Kira, J., Itoyama, Y., Koyanagi, Y., Tateishi, J., Kishikawa, M., Akizuki, S., Kobayashi, I., Toki, N., Sueishi, K., Sato, H., et al. (1992) · Annals of Neurology · doi:10.1002/ana.410310108 · Cited by 84 · see citing works
Harrington, W. J., Sheremata, W. A., Snodgrass, S. R., Emerson, S., Phillips, S., & Berger, J. R. (1991) · AIDS Research and Human Retroviruses · doi:10.1089/aid.1991.7.1031 · Cited by 67 · see citing works
High‐dose zidovudine induction in HTLV‐I‐associated myelopathy
Sheremata, W. A., Benedict, D., Squilacote, D. C., Sazant, A., & Defreitas, E. C. (1993) · Neurology · doi:10.1212/wnl.43.10.2125 · Cited by 59 · see citing works
The effect of zidovudine on chronic myelopathy associated with HTLV-1
Gout, O., Antoine Gessain, A., Iba-Zizen, M. T., Kouzan, S., Bolgert, F., de-Th�, G., & Lyon‐Caen, O. (1991) · Journal of Neurology · doi:10.1007/bf00315691 · Cited by 46 · see citing works
Intermittent high-dose vitamin C therapy in patients with HTLV-I associated myelopathy.
Kataoka, A., Imai, H., Inayoshi, S., & Tsuda, T. (1993) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.56.11.1213 · Cited by 39 · see citing works
Interferon-alpha treatment in HTLV-I-associated myelopathy
Shibayama, K., Nakamura, T., Nagasato, K., Shirabe, S., Tsujihata, M., & Nagataki, S. (1991) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(91)90256-7 · Cited by 27 · see citing works
Treatment of HTLV-I-associated myelopathy with high-dose intravenous gammaglobulin
Kuroda, Y., Takashima, H., Ikeda, A., Endo, C., Neshige, R., Kakigi, R., & Shibasaki, H. (1991) · Journal of Neurology · doi:10.1007/bf00315327 · Cited by 27 · see citing works
Midline hyperplasia with malformation of the fornical system
Friede, R. L., & Briner, J. (1978) · Neurology · doi:10.1212/wnl.28.12.1302 · Cited by 15 · see citing works
IMMUNOPHENOTYPING OF LYMPHOCYTES BY FLOW CYTOMETRY
Fleisher, T. A. (1994) · Immunology and Allergy Clinics of North America · doi:10.1016/s0889-8561(22)00773-1 · Cited by 10 · see citing works
Self-citationMatsuo, H., Nakamura, T., Tsujihata, M., Motomura, M., Nagasato, K., & Nagataki, S. (1989) · Japanese Journal of Medicine · doi:10.2169/internalmedicine1962.28.328 · Cited by 6 · see citing works
Flagged first, then by citations
2 of the 30 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Bielekova, B., Catálfamo, M., Reichert-Scrivner, S. A., Packer, A., Černá, M., Waldmann, T. A., McFarland, H. F., Henkart, P. A., & Martinꝉ, R. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0601335103 · Cited by 597 · see citing works
Self-citationWaldmann, T. A. (2001) · Immunity · doi:10.1016/s1074-7613(09)00091-0 · Cited by 433 · see citing works
Self-citationYamano, Y., Nagai, M., Brennan, M. B., Mora, C. A., Soldan, S. S., Tomaru, U., Takenouchi, N., Izumo, S., Osame, M., & Jacobson, S. (2002) · Blood · doi:10.1182/blood.v99.1.88 · Cited by 277 · see citing works
Self-citationMatsuzaki, T. (2001) · Journal of NeuroVirology · doi:10.1080/13550280152403272 · Cited by 152 · see citing works
Inflammatory manifestations of HTLV-1 and their therapeutic options
Martin, F., Taylor, G. P., & Jacobson, S. (2014) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2014.966690 · Cited by 148 · see citing works
Self-citationImmunotherapy for Ovarian Cancer: What's Next?
Kandalaft, L. E., Powell, D. J., Singh, N., & Coukos, G. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.2369 · Cited by 148 · see citing works
Quantitation of HTLV-I proviral load by a TaqMan real-time PCR assay
Dehée, A., Césaire, R., Désiré, N., Lézin, A., Bourdonné, O., Béra, O., Plumelle, Y., Smadja, D., & Nicolas, J. (2002) · Journal of Virological Methods · doi:10.1016/s0166-0934(01)00445-1 · Cited by 135 · see citing works
Waldmann, T. A. (2007) · Journal of Clinical Immunology · doi:10.1007/s10875-006-9060-0 · Cited by 132 · see citing works
Self-citationContrasting Roles of IL-2 and IL-15 in the Life and Death of Lymphocytes
Waldmann, T. A., Dubois, S. P., & Tagaya, Y. (2001) · Immunity · doi:10.1016/s1074-7613(01)00093-0 · Cited by 115 · see citing works
Self-citationMoura, I. C. (2004) · Blood · doi:10.1182/blood-2003-07-2440 · Cited by 114 · see citing works
The IL-2/IL-15 Receptor Systems: Targets for Immunotherapy
Waldmann, T. A. (2002) · Journal of Clinical Immunology · doi:10.1023/a:1014416616687 · Cited by 89 · see citing works
Self-citationDaclizumab Therapy for Multiple Sclerosis
Bielekova, B. (2012) · Neurotherapeutics · doi:10.1007/s13311-012-0147-4 · Cited by 88 · see citing works
Azimi, N., Jacobson, S., Leist, T. P., & Waldmann, T. A. (1999) · PubMed · Cited by 85 · see citing works
Self-citationAfonso, P. V., Mekaouche, M., Mortreux, F., Toulza, F., Moriceau, A., Wattel, E., Antoine Gessain, A., Bangham, C. R. M., Dubreuil, G., Plumelle, Y., et al. (2010) · Blood · doi:10.1182/blood-2010-02-270751 · Cited by 80 · see citing works
Azimi, N., Jacobson, S., Leist, T. P., & Waldmann, T. A. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.7.4064 · Cited by 80 · see citing works
Self-citationDaclizumab (anti-Tac, Zenapax) in the treatment of leukemia/lymphoma
Waldmann, T. A. (2007) · Oncogene · doi:10.1038/sj.onc.1210368 · Cited by 79 · see citing works
Self-citationPhillips, K. E., Herring, B., Wilson, L., Rickford, M. S., Zhang, M., Goldman, C. K., Tso, J. Y., & Waldmann, T. A. (2000) · PubMed · Cited by 79 · see citing works
Self-citationJu, W., Zhang, M., Jiang, J.-K., Thomas, C. J., Oh, U., Bryant, B. R., Chen, J., Sato, N., Tagaya, Y., Morris, J. C., et al. (2010) · Blood · doi:10.1182/blood-2010-09-305425 · Cited by 76 · see citing works
Self-citationInterferon‐β1a therapy in human T‐lymphotropic virus type I–associated neurologic disease
Oh, U., Yamano, Y., Mora, C. A., Ohayon, J., Bagnato, F., Butman, J. A., Dambrosia, J., Leist, T. P., McFarland, H., & Jacobson, S. (2005) · Annals of Neurology · doi:10.1002/ana.20429 · Cited by 74 · see citing works
Self-citationAnti-CD25 (daclizumab) monoclonal antibody therapy in relapsing–remitting multiple sclerosis
Martinꝉ, R. (2011) · Clinical Immunology · doi:10.1016/j.clim.2011.10.008 · Cited by 71 · see citing works
Corticosteroid therapy in TSP/HAM patients: The results from a 10 years open cohort
Croda, M. G., de Oliveira, A. C. P., Vergara, M. P. P., Bonasser, F., Smid, J., Duarte, A. J. D. S., & Casseb, J. (2008) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2008.01.004 · Cited by 70 · see citing works
Sakai, J. A., Nagai, M., Brennan, M. B., Mora, C. A., & Jacobson, S. (2001) · Blood · doi:10.1182/blood.v98.5.1506 · Cited by 69 · see citing works
Self-citationOh, U., & Jacobson, S. (2008) · Neurologic Clinics · doi:10.1016/j.ncl.2008.03.008 · Cited by 63 · see citing works
Self-citationNozuma, S., & Jacobson, S. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.00885 · Cited by 51 · see citing works
Self-citationImmunovirological markers in HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP)
Enose-Akahata, Y., & Jacobson, S. (2019) · Retrovirology · doi:10.1186/s12977-019-0499-5 · Cited by 49 · see citing works
Self-citationDaclizumab (anti-CD25) in multiple sclerosis
Pfender, N., & Martinꝉ, R. (2014) · Experimental Neurology · doi:10.1016/j.expneurol.2014.04.015 · Cited by 41 · see citing works
HTLV-I-associated myelopathy manifested after renal transplantation
Nakatsuji, Y., Sugai, F., Watanabe, S., Kaido, M., Koguchi, K., Abe, K., & Sakoda, S. (2000) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(00)00332-4 · Cited by 41 · see citing works
Monoclonal Antibodies and Recombinant Immunoglobulins for the Treatment of Multiple Sclerosis
Gensicke, H., Leppert, D., Yaldizli, Ö., Lindberg, R. L. P., Mehling, M., Kappos, L., & Kühle, J. (2011) · CNS Drugs · doi:10.2165/11596920-000000000-00000 · Cited by 40 · see citing works
The efficacy and safety of daclizumab and its potential role in the treatment of multiple sclerosis
Milo, R. (2014) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285613504021 · Cited by 38 · see citing works
Martin, F., Castro, H., Gabriel, C., Adonis, A., Fedina, A., Harrison, L., Brodnicki, L., Demontis, M. A., Babiker, A. G., Weber, J. N., et al. (2012) · PLoS Neglected Tropical Diseases · doi:10.1371/journal.pntd.0001675 · Cited by 38 · see citing works
Koon, H. B., Severy, P. B., Hagg, D. S., Butler, K. L., Hill, T., Jones, A. G., Waldmann, T. A., & Junghans, R. P. (2005) · Leukemia Research · doi:10.1016/j.leukres.2005.06.007 · Cited by 36 · see citing works
Self-citationKandalaft, L. E., Singh, N., Liao, J. B., Facciabene, A., Berek, J. S., Powell, D. J., & Coukos, G. (2009) · Gynecologic Oncology · doi:10.1016/j.ygyno.2009.11.001 · Cited by 35 · see citing works
Cytokine Therapies in Neurological Disease
Azodi, S., & Jacobson, S. (2016) · Neurotherapeutics · doi:10.1007/s13311-016-0455-1 · Cited by 35 · see citing works
Self-citationNakamura, T. (2009) · PubMed · Cited by 32 · see citing works
Emerging Therapies: Spectrum of Applications of Monoclonal Antibody Therapy
Waldmann, T. A. (2000) · Hematology · doi:10.1182/asheducation-2000.1.394 · Cited by 32 · see citing works
Self-citationDaclizumab: Development, Clinical Trials, and Practical Aspects of Use in Multiple Sclerosis
Baldassari, L. E., & ROSE, J. W. (2017) · Neurotherapeutics · doi:10.1007/s13311-017-0553-8 · Cited by 30 · see citing works
T-cell receptors for cytokines: Targets for immunotherapy of leukemia/lymphoma
Waldmann, T. A. (2000) · Annals of Oncology · doi:10.1093/annonc/11.suppl_1.s101 · Cited by 29 · see citing works
Self-citationMonaco, M. C., Soldan, S. S., Su, C., Clauze, A., Cooper, J. F., Patel, R. J., Lu, F., Hughes, R. J., Messick, T. E., Andrada, F. C., et al. (2023) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000200149 · Cited by 27 · see citing works
Self-citationVolkó, J., Kenesei, Á., Zhang, M., Várnai, P., Mocsár, G., Petrus, M. N., Jambrovics, K., Balajthy, Z., Müller, G., Bodnár, A., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1901382116 · Cited by 26 · see citing works
Self-citationImmunopathogenesis of HTLV-I-associated myelopathy/tropical spastic paraparesis
Nakamura, T. (2000) · Annals of Medicine · doi:10.3109/07853890009002030 · Cited by 25 · see citing works
Prospects for the management of human T-cell lymphotropic virus type 1-associated myelopathy.
Martin, F., & Taylor, G. P. (2011) · PubMed · Cited by 24 · see citing works
HTLV-1 and Its Neurological Complications
Khan, R. B., Bertorini, T. E., & Levin, M. C. (2001) · The Neurologist · doi:10.1097/00127893-200109000-00001 · Cited by 24 · see citing works
Self-citationHumanized Anti-CD25 Antibody Treatment with Daclizumab in Multiple Sclerosis
Martinꝉ, R. (2007) · Neurodegenerative Diseases · doi:10.1159/000109934 · Cited by 22 · see citing works
Current State of Therapeutics for HTLV-1
Wang, T. T., Hirons, A., Doerflinger, M., Morris, K. V., Ledger, S., Purcell, D. F. J., Kelleher, A. D., & Ahlenstiel, C. L. (2024) · Viruses · doi:10.3390/v16101616 · Cited by 22 · see citing works
“…Topical or systemic corticosteroids and mydriatics [263] HTLV-1-associated Sjögren’s Syndrome Artificial lubricants such as saliva/tears replacement solutions coupled with systemic pharmacotherapy with pilocarpine hydrochloride [264] HTLV-1-associated Hashimoto’s thyroiditis and Graves’ disease”
BackgroundMechanisms of Antibody Immunotherapy on Clonal Islet Reactive T Cells
van de Linde, P., Tysma, O. M. H., Medema, J. P., Hale, G., Waldmann, H., Roelen, D. L., & Roep, B. O. (2006) · Human Immunology · doi:10.1016/j.humimm.2006.02.027 · Cited by 21 · see citing works
Clinical trial of a humanized anti‐IL‐2/IL‐15 receptor β chain in HAM/TSP
Enose‐Akahata, Y., Oh, U., Ohayon, J. M., Billioux, B. J., Massoud, R., Bryant, B. R., Vellucci, A., Ngouth, N., Cortese, I. C. M., Waldmann, T. A., et al. (2019) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.50820 · Cited by 17 · see citing works
Self-citationMassoud, R., Enose‐Akahata, Y., Tagaya, Y., Azimi, N., Basheer, A., & Jacobson, S. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1412626112 · Cited by 15 · see citing works
Self-citationvan de Linde, P., van der Boog, P. J. M., Tysma, O. M. H., Elliott, J. F., Roelen, D. L., Claas, F. H. J., de Fijter, J. W., & Roep, B. O. (2007) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2007.03400.x · Cited by 15 · see citing works
Enose-Akahata, Y., Ngouth, N., Ohayon, J., Mandel, M., Chavin, J., Turner, T. J., & Jacobson, S. (2021) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000986 · Cited by 13 · see citing works
Self-citationNeurologic disease due to HTLV-1 infection
McKendall, R. R. (2014) · Handbook of clinical neurology · doi:10.1016/b978-0-444-53488-0.00024-9 · Cited by 12 · see citing works
Ghezeldasht, S. A., Mosavat, A., & Rezaee, S. A. (2024) · Reviews in Medical Virology · doi:10.1002/rmv.2567 · Cited by 11 · see citing works
Fukushima, N., Nishiura, Y., Nakamura, T., Kohno, S., & Eguchi, K. (2007) · Internal Medicine · doi:10.2169/internalmedicine.46.6118 · Cited by 10 · see citing works
Emerging Therapies: Spectrum of Applications of Monoclonal Antibody Therapy
Waldmann, T. A., Levy, R., & Coller, B. S. (2000) · Hematology · doi:10.1182/asheducation.v2000.1.394.394 · Cited by 10 · see citing works
Self-citationDaclizumab, an IL-2 modulating antibody for treatment of multiple sclerosis
Sheridan, J. P., Robinson, R. R., & ROSE, J. W. (2013) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2014.865516 · Cited by 8 · see citing works
A critical appraisal of daclizumab use as emerging therapy in multiple sclerosis
D’Amico, E., Messina, S., Caserta, C., & Patti, F. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.1032937 · Cited by 4 · see citing works
Daclizumab for the treatment of adults with relapsing forms of multiple sclerosis
Osherov, M., & Milo, R. (2017) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1366854 · Cited by 4 · see citing works
Pathogenesis and treatment of human T-cell lymphotropic virus Type I-associated myelopathy
Nagai, M., & Osame, M. (2002) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2.6.891 · Cited by 2 · see citing works
Human T-Cell Lymphotropic Virus Type 1 Infection
Jacobson, S., & Massoud, R. (2012) · Springer eBooks · doi:10.1007/978-3-0348-0425-7_8 · Cited by 2 · see citing works
Self-citationManifestazioni neurologiche associate al virus HTLV-1
Olindo, S., & Jeannin, S. (2014) · EMC - Neurologia · doi:10.1016/s1634-7072(14)67222-6 · Cited by 1 · see citing works
Basiliximab (Simulect®) and Daclizumab (Zenapax®)
Mahmud, N., Taner, C. B., & Ahsan, N. (2014) · doi:10.1002/9783527682423.ch47 · Cited by 1 · see citing works
The NK cell as a new player in the pathogenesis of HTLV-I associated neurologic disease
Jacobson, S. (2010) · Virulence · doi:10.4161/viru.1.1.10327 · Cited by 1 · see citing works
Self-citationEmerging Therapies: Spectrum of Applications of Monoclonal Antibody Therapy
Waldmann, T. A., Levy, R., & Coller, B. S. (2000) · Hematology · doi:10.1182/asheducation.v2000.1.394.20000394 · Cited by 1 · see citing works
Self-citationWhat Is the Future of Immunotherapy in Ovarian Cancer?
Kandalaft, L. E., Balint, K., Berek, J. S., & Coukos, G. (2013) · Springer eBooks · doi:10.1007/978-0-85729-910-9_29
Human T-Cell Lymphotropic Viruses (HTLVs)
Jacobson, S., & Massoud, R. (2014) · Encyclopedia of the Neurological Sciences · doi:10.1016/b978-0-12-385157-4.00380-8
Self-citationTargeted Molecular Therapy for Patients with Ovarian Cancer
Farghaly, S. A. (2013) · Springer eBooks · doi:10.1007/978-1-4614-8271-0_12
Papel dos microRNAs humanos na infecção pelo HTLV-1
Nicolete, L. D. D. F. (2009) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.60.2009.tde-02032009-112507
Monoclonal Antibodies (mAb) in the Therapy of T-Cell Lymphomas
Alinari, L., Porcu, P., & Coiffier, B. (2012) · Humana Press eBooks · doi:10.1007/978-1-62703-170-7_14
Manifestazioni neurologiche legate all’“human T-cell leukemia/lymphoma virus” tipo 1 (HTLV-1)
Olindo, S., Jeannin, S., & Lézin, A. (2021) · EMC - Neurologia · doi:10.1016/s1634-7072(21)44999-8
Takao, N., & Yamano, Y. (2022) · Clinical and Experimental Neuroimmunology · doi:10.1111/cen3.12687
Encephalitis in Immunocompetent Patients
Booss, J., & Esiri, M. M. (2014) · ASM Press eBooks · doi:10.1128/9781555817831.ch14
(2020) · Elsevier eBooks · doi:10.1016/b978-0-323-55512-8.00038-7
Targeted Molecular Therapy for Ovarian Cancer Patients
Farghaly, S. A. (2022) · Springer eBooks · doi:10.1007/978-3-031-09169-8_11
Unmasking HAM/TSP: understanding HTLV-1-driven neurological disease
Letafati, A., Tajik, S., Rad, M. V., Shahbahrami, R., Moulaeian, M., Norouzi, M., & Mozhgani, S. (2026) · Journal of NeuroVirology · doi:10.1007/s13365-026-01305-x
Effet du valproate sur l'expression du génome viral dans les cellules infectées par HTLV-1
Belrose, G. (2011) · theses.fr (ABES) · doi:10.70675/39a69ddez13c8z43b6z910dz5aba75f31d16
Nakamura, T., & Satoh, K. (2026) · Pathogens · doi:10.3390/pathogens15050555
Liu, L. (2026) · Reviews in Medical Virology · doi:10.1002/rmv.70207
- Authors
- Lehky, T. J., Levin, M. C., Kubota, R., Bamford, R. N., Flerlage, A. N., Soldan, S. S., Leist, T. P., Xavier, A., White, J. D., Brown, M., Fleisher, T. A., Top, L. E., Light, S., McFarland, H. F., Waldmann, T. A., & Jacobson, S.
- Affiliations
- National Institutes of Health (US)
- National Institute of Neurological Disorders and Stroke (US)
- National Cancer Institute (US)
- Corresponding author
- Lehky, Tanya J.
- ORCID
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 1998-12
- Volume
- 44
- Issue
- 6
- Pages
- 942-947
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W2168437273
- Cited by
- 80
- References
- 30
- Citations by year
- 2026: 3 · 2024: 2 · 2023: 1 · 2022: 2 · 2021: 2 · 2020: 1 · 2019: 5 · 2017: 3 · 2016: 1 · 2015: 2 · 2014: 7 · 2013: 4 · 2012: 4
- FWCI
- 1.66
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Annals of Neurology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and Retrovirus Studies
- Health Sciences › Medicine › Surgery › Infectious Diseases and Tuberculosis
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Keywords
- HTLV-1, HAM/TSP, proviral load, lymphoproliferation, CD4+ T cells, activated T cells, viral load reduction, immune activation, retroviral infection, neurological disorders
- MeSH terms
- Antibodies, Blood Cells, Cell Division, Humans, Lymphocytes, Proviruses, Human T-lymphotropic virus 1, Receptors, Interleukin-2, Paraparesis, Tropical Spastic, Immunophenotyping, Lymphocyte Subsets, Treatment Outcome, Viral Load
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
